Work

Position paper of the European Society of Cardiology–working group of coronary pathophysiology and microcirculation: obesity and heart disease

Year: 2017
Type: article
Abstract: The epidemic of obesity is recognized as one of the most important public health problems facing the world today. According to 2014 World Health Organization (WHO) data,1 39% of adults worldwide are overweight (body mass index, BMI ≥ 25 kg/m2) and 13% of adults are obese (BMI ≥ 30 kg/m2). Thus, more than half a billion adults worldwide are classified as obese. The prevalence of obesity varies by geographical region, gender and income level. The highest prevalence is found in the USA (61% overweight, 27% obese), closely followed by Europe (59% overweight, 23% obese), with the lowest prevalence in South–East Asia (22% overweight, and 5% obese). In Europe, the vast majority of countries have an overweight prevalence of more than 60%.1 Asians generally have a higher percentage of body fat than Caucasians of the same age, sex and BMI. Even below the usual cut-off of BMI = 25 kg/m2 Asian people seem to be at increased risk for type 2 diabetes.2 This may have implications for obesity diagnostic criteria. Indeed, the proposed optimal BMI cut-off values by WHO in Asian populations seems to vary from 22 to 25 kg/m2 based on the ethnic background. A Consensus Statement for Diagnosis of Obesity, Abdominal Obesity and the Metabolic Syndrome for Asian Indians has suggested the following BMI cut-off values: normal BMI = 18.0–22.9 kg/m2; overweight = 23.0–24.9 kg/m2; and obesity > 25 kg/m2.3 Thus it is indeed debatable whether uniform BMI cut-off values to diagnose obesity and/or for cardiovascular risk stratification purposes can be use worldwide. The use of additional anthropometric measurements e.g. waist-circumference or CT based quantification of abdominal/subcutaneous fat volume could help to better delineate obesity and risk parameters and to implement preventive strategies against obesity in each specific ethnic scenario. See Supplementary material online, Appendix. Obesity and overweight are risk factors for the development atherosclerosis. The adipose tissue (AT) was traditionally considered an energy storage organ. However, a large body of evidence highlights the AT as an active endocrine organ that secretes numerous hormones and bioactive molecules.4 These adipokines (or adipocytokines) can act in an endocrine, autocrine and paracrine manner regulating not only AT metabolism, but also other organs, such as liver, muscle, the central nervous system and pancreas. Thus, adipokines represent key regulators of glucose level, lipid metabolism, blood pressure, inflammation, and oxidative stress.5 Several lines of evidence point to adipokine deregulation as the link between obesity and development of cardiovascular disease (CVD).6 Various adipokines, including adiponectin, leptin, omentin, and resistin, have been implicated in modulating the atherogenic environment of the vessel wall by affecting endothelial and arterial smooth muscle cell function, as well as macrophages. Interestingly, certain AT depots show a stronger correlation with obesity-associated co-morbidities than total AT mass, reinforcing the concept of depot-specific metabolic functions.7 The principal depots of white AT (WAT) include the visceral AT (VAT), surrounding the visceral organs, the subcutaneous AT (SAT) located below the skin, and the ectopic AT which consists of non-storage depots. Although overall fat mass is important for the development of obesity-associated co-morbidities, VAT accumulation is an independent risk factor for obesity-related metabolic and CVD.8 This differential impact on cardiovascular risk seems to be related to the adipokines secreted from the different fat depots. Specifically, leptin, mainly secreted by SAT, is positively correlated with body fat whereas adiponectin which is more influenced by VAT is reduced in obesity. One particular ectopic AT depot that has attracted major attention is fat surrounding the vasculature, also known as perivascular AT (PVAT), which appears to play an essential role in the control of vascular function and remodelling.9 In lean individuals PVAT exerts vasodilatory and anti-inflammatory functions. These beneficial actions of PVAT are blunted in obesity where the pro-inflammatory state leads to insulin resistance and increased oxidative stress, thereby contributing to vascular dysfunction and remodelling.9 See Supplementary material online, Appendix. Brown AT (BAT) has a different cellular structure, metabolic profile, and function than WAT. Brown AT dissipates energy by uncoupled UCP-1-mediated respiration resulting in heat production (thermogenesis), increased fatty acid oxidation and decreased lipid storage. Brown AT in humans has been traditionally found in neonates; however, the presence of some BAT depots in human adults has also been reported.10 Initially identified in rodents, beige AT (‘brite’, ‘brown-like’, or ‘inducible brown’ AT) is an inducible form of thermogenic AT with a low UCP-1 content in basal conditions that can be induced to increase energy consumption.11 Although its origin has not been clearly identified yet, clusters of these brite adipocytes can be found within WAT in response to certain activators.12 Interventions increasing the number and/or activity of BAT or inducing the formation of beige adipocytes arise as promising therapeutic options to treat obesity and its related metabolic disturbances. In healthy conditions, AT is composed of a variety of cells including mature adipocytes, adipocyte progenitors, endothelial cells, fibroblasts, and immune cells (primarily resident anti-inflammatory M2-like macrophages together with T regulatory cells (Tregs) and eosinophils). Yet, as AT expands, adipocytes enlarge and there is a rapid and active recruitment of monocytes from the blood into the obese AT, where they differentiate into M1 polarized macrophages with pro-inflammatory activity.13 Obesity-induced adipocytes release free fatty acids (FFA), stimulate macrophages via toll-like receptor-4 resulting in NF-κB activation and TNF-α production. In turn, macrophage-derived TNF-α activates the adipocytes to secrete MCP-1, intercellular adhesion molecule-1 (ICAM-1) and IL-6. Both, adipocyte-derived MCP-1 expression and macrophage-related c-Jun kinases promote further monocyte infiltration.14 See Supplementary material online, Appendix. This chronic pro-inflammatory state affects the vascular endothelium, platelets, and other circulating cells leading to an upregulation of procoagulant factors and adhesion molecules, downregulation of anti-coagulant regulatory proteins, increased thrombin generation, and enhanced platelet activation.15 , 16 Indeed, obese patients have increased plasma concentration of FVII, thrombin, thrombin–antithrombin complexes, circulating monocyte tissue factor procoagulant activity, decreased fibrinolytic activity, and platelet hyperactivity. Noteworthy, platelet activation has implications for both thrombosis and inflammation. Thus, several platelet activation markers are elevated in obese patients including the mean platelet volume, circulating levels of platelet microparticles, thromboxane B2 metabolites, soluble P-selectin, and platelet-derived CD40L.17 Causes of enhanced platelet activation include the altered exposure and/or increased expression of surface receptors for agonists and adhesion molecules, decreased membrane fluidity, altered platelet metabolism, disruptions in intraplatelet signalling, and increased oxidative stress.18 Chronic inflammation is also associated with the deregulation of endogenous anticoagulant mechanisms, including tissue factor pathway inhibitor, antithrombin, and the protein C anticoagulation system leading to imbalanced haemostasis and an increased risk of thrombosis.19 Upon FFA and TNF-α exposure AT also releases PAI-1, the most important physiologic inhibitor of plasminogen. Thus, obesity is consistently associated with impaired fibrinolysis further promoting the pro-thrombotic state (Figure 1).17 Simplified diagram of obesity-related changes in inflammation and thrombosis. Under lean circumstances, adipose tissue is composed of a variety of immune cells including resident anti-inflammatory M2-like macrophages together with T regulatory cells and eosinophils. As adipose tissue expands adipocytes release free fatty acids (FFA) which stimulate macrophages to induce TNF-α production. In turn, macrophage-derived TNF-α activates adipocytes to secrete monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1) and interleukin (IL)-6 enhancing the recruitment of blood monocytes into the obese adipose tissue where they are transformed into M1 polarized macrophages with pro-inflammatory potential. In addition, expansion of adipose tissue is accompanied by a reduction in eosinophils and Tregs and an increase in neutrophils, B cells, mast cells, and interferon γ-producing Th1 and CD8+T cells that overall forms a pro-inflammatory milieu. Concomitantly, adipose tissue expansion is accompanied by an increase oxidative stress and a decrease in the release of an adiponectin, an adipokine with protective features. The perpetuation of this vicious cycle leads to the development of a low-grade systemic inflammation that induces endothelial dysfunction, a hypercoagulable sate and increases platelet reactivity leading to an overall increase risk of thrombosis. See Supplementary material online, Appendix. The normal heart uses both FFA and glucose as substrates to maintain its energy balance (Figure 2). In obesity, plasma levels of FFA and triacylglycerol increase, modifying not only uptake of FFA, but also that of glucose.20 – 22 This results in intracellular accumulation of lipids and thus alterations of cardiac metabolism, primarily due to excessive fatty acids utilization as substrate. Interestingly, this pathway is accentuated in obese women.23 In fact, gender independently predicts lower glucose utilization and myocardial oxygen consumption, both of which are correlated with BMI in females but not males.23 Simplified schema of obesity-induced cardiac cell dysfunction leading to impaired metabolic regulation of coronary microcirculation. In obesity, fatty acid availability and uptake increases leading to lipotoxicity, reduced glucose consumption and mitochondrial energy dysbalance and uncoupling. This results in reduced adenosine triphosphate (ATP) production and mechanical performance of the heart, and increased H2O2 production. These events favour the development of a mismatch between coronary blood flow supply and cardiac demands. Regardless of gender the increased oxidation of FFA still cannot keep up with the accumulation of FFA resulting in the formation and accumulation of lipotoxins such as ceramides. A more detailed picture emerged from studies showing that increased levels of FFA inhibit glucose uptake driven by insulin.21 , 22 In addition, the mitochondrial oxidative capacity is reduced, while mitochondrial uncoupling is increased, which, together with decreased glucose utilization, impairs myocardial energetics and consequently mechanical performance.20 Finally, increased levels of FFA inhibit oxidation of pyruvate and pyruvate dehydrogenase activity. These mechanisms may contribute to the systolic dysfunction, increased end-diastolic volume and cardiac hypertrophy.20 , 21 , 23–25 See Supplementary material online, Appendix. Obesity is associated with altered endothelial function that shifts the balance towards constriction by impairing release and activity of relaxing factors and concomitantly enhancing production of vasoconstrictors. The resulting enhanced vascular tone compromises regional blood flow to different tissues and organs (including the coronary circulation) and consequently impairs organ function. A standard approach to examine endothelial function in humans is the assessment of flow-induced dilation and multiple studies have demonstrated its impairment in obese subjects.26 Moreover, BMI was inversely related to flow-dependent dilation and even modest voluntary weight gain (∼4 kg) attenuated endothelial function reversibly in young healthy adults.27 Impaired dilator responses to endothelial agonists have also been demonstrated in isolated small arteries from obese subjects.28 In experimental animal studies the impaired endothelial function has been related to attenuation of NO bioavailability due to exaggerated oxidative stress and production of reactive oxygen species (ROS) degrading NO, with xanthine oxidase as well as NADPH oxidase as suggested sources of ROS production.28 On the other hand, vasoconstrictor influence is enhanced (Figure 3). This is in part due to an enhanced sympathetic tone in obese subjects29 but the endothelium also contributes by releasing the potent vasoconstrictor endothelin-1 (ET-1) as well as by cyclooxygenase (COX) dependent constrictor pathways (specifically COX-1).30 , 31 Effects of obesity on vascular function. A shift from vasodilator to vasoconstrictor mediators that is related to enhanced oxidative stress was observed in many animal models of obesity. This common theme in diverse pathophysiologic settings includes decreased bioavailability of NO and enhanced release of vasoconstrictor mediators (COX products, endothelin-1). In addition, the beneficial effects of perivascular fat (PVAT) turn bad in obesity with decreased release of vasodilatative adiponectin and of a possible adipocyte-derived relaxing factor (ADRF) as well as enhanced secretion of leptin and pro-inflammatory mediators that exert detrimental effects on endothelial function. See Supplementary material online, Appendix. There is ample evidence stemming from both clinical and experimental studies that obesity is an independent risk factor for coronary microvascular dysfunction.28 , 32 , 33 In addition, studies indicate that obesity is associated with perturbations in the adjustments in coronary blood flow to increased metabolic demands (Figure 4).28 Mechanisms of coronary microvascular dysfunction in obesity. Obesity-related microvascular tone control and microvascular structure regulation through changes in mechanical forces, endothelial function and neurohumoral, adipokine, and cytokine secretion. See Supplementary material online, Appendix. Increased sympathetic nervous system (SNS) activity is known to be causally involved in heart failure (HF) and hypertension development and flags subjects at increased risk for future cardiovascular events.34 Obesity and SNS overactivity are closely inter-related and this may partly mediate the increased risk of obesity-related cardiovascular disease. Obese individuals have increased catecholamine urinary levels and whole-body noradrenaline plasma spillover compared with lean subjects.35 See Supplementary material online, Appendix. See Supplementary material online, Appendix. Obesity represents an independent risk factor for the development of ischaemic heart disease (IHD), cerebrovascular disease and HF. The INTERHEART study found that obesity, measured by the waist-to-hip ratio, exhibits a graded and highly significant association with acute myocardial infarction (AMI) risk worldwide.36 Similarly, the Prospective Studies Collaboration analysing 57 prospective studies through North America and Europe revealed that BMI is a strong predictor of overall mortality36 especially abdominal obesity.37–39 A prospective, multicentre international registry found that in individuals without known CAD, an increase in BMI was positively associated with greater prevalence, extent and severity of CAD.40 Higher BMI categories associated with an increase in and increased risk of In patients with coronary a significant between BMI and gender in to risk of and cardiovascular was obese an increased risk of and cardiovascular overweight a decreased risk of compared with normal weight Similarly, in a with overweight, and obese patients lower compared with patients with normal be however, that obese patients as in obese patients than in and that obese patients which could have influenced they a of and which could be by the in additional factor could be that in was more in overweight and obese inhibitor, and and coronary more in overweight and obese Obesity has consistently emerged as a risk factor for The risk of increases with BMI. In the an 5% increase in risk increase in BMI was in both and Obesity is also a risk factor for the of to In the and the In risk BMI is as a major risk The evidence consistently indicate a between development of obesity and risk for the for such an association are still Indeed, obesity may with multiple additional factors to contribute to As hypertension is associated with obesity and it is as well a known risk factor for and has also been associated with an increased risk for from risk increase in to in Obesity, hypertension as well as have common risk as they are of the metabolic which, in turn, is a risk factor for The metabolic and obesity seem to increase and promote and AT have been suggested to be factors associated with and and with demonstrated that but not or visceral abdominal was associated with these a study that AT such as A of the but not induce in turn, that AT may be more important than its overall as it has also been for other fat See Supplementary material online, Appendix. Obesity is an independent risk factor for HF. and dysfunction due to increased endothelial dysfunction, activation and increased oxidative stress may in HF. of the factors are a of metabolic activity of excessive fat tissue and the health effects of obesity in it was that obese patients with a than of normal However, in with many studies even showing a better in patients with increased BMI. individuals with and found that higher BMI was associated with better In higher percentage of body fat and higher BMI only to lower as independent of This is also in coronary heart disease The mechanisms for this The was to changes in enhanced against and increased and metabolic in obese several in the of the may be in to HF. of these studies have on BMI and a on percentage of body and there is other Obese individuals by a age, higher blood pressure, better systolic function, and better and function. The of in obese patients was especially only the Finally, many of the studies not for and chronic disease and subjects which may have to a See Supplementary material online, Appendix. Obese individuals be in cardiovascular to body weight and increase activity thereby other cardiovascular risk such as and The standard for the and of obesity is energy and increasing activity. of the energy of the still that increased fat to weight whereas reduced fat promote weight However, to is and for gain In addition, a for weight only in the of In the the of fat as has in decreased fat consumption as percentage of energy in the but increasing of obesity and have not most fat content was with On the other hand, can be beneficial for cardiovascular health are such as fatty acids or fatty acids See Supplementary material online, Appendix. In also is a to against obesity. The World Health Organization 30 or more a and to increase this to a a on age, and In a including studies = both and a reduction of body weight and also of visceral which is a stronger predictor of and Interestingly, the to decrease body whereas to have effects in visceral are to maintain a lower or in and lower or in of an overweight or obese a assessment and includes of the of obesity and overall health not only weight and of body weight but also to control other risk of an overall risk includes the of the presence of abdominal fat and the presence of cardiovascular risk factors and/or related to obesity. conditions that risk include other type 2 and but also fatty disease. or more risk factors also is for patients with a BMI > 30 as well as patients with a BMI between 25 and or a > > and or more risk , The of is to or the of obesity. through energy and/or metabolic health and obesity-associated and has been that of body weight is associated with increased insulin plasma lipid and decreased blood weight of of body weight is a The of weight be each A that is to help a of be activity be an part of however, have that overall and cardiovascular is increased weight This has been related to the of such studies to from weight Thus, the observed weight be the of co-morbidities that people to from more have that weight for is associated with a significant reduction in in overweight and the that the the the greater the of weight cardiac in patients with was a of to promote weight may be for but is to subjects with a BMI > or have a BMI > obesity-related risk factors or The role of has been of the for and many are by the and the and for and use in weight material online, the most which of fat from the on are A of found that a number of in the significant weight with 21 and of and weight A more on weight on a reduction of BMI by kg/m2 in subjects with and an increase by kg/m2 in subjects in the at decreased in the but increased in the has been for without in the There however, some its The most effects include and The percentage of patients the most is In with in with and weight in obese without major See Supplementary material online, Appendix. is an for and patients with obesity. with a BMI of kg/m2 are at and with a BMI kg/m2 are at Several to as have been to treat obesity. See Supplementary material online, Appendix. See Supplementary material online, Appendix. See Supplementary material online, Appendix. In obesity is a health and a as it represents a major risk factor for including CAD, and HF. in of the of obesity, the fat tissues and factors and for the cardiovascular system have been the is that a approach is to or the obesity-associated future is to the pathways the effects of AT and obesity on cardiovascular in to and of obese of in to body weight regulation and the of weight of the specific effects of AT and obesity on the and and as well as in systemic inflammation. gain on the of obesity and and fat on regulation and function. study the effects of obesity, without the presence of conditions such as and to the to extent obesity coronary and better the optimal weight in the the of the obesity it be that the of weight is better energy balance and in of weight and to and Supplementary material is at of and of to of Health and to the of and of and of the of to and to and with of the of and to to of
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2612075601
FWCI: 7.779
Cites: 68
Cited by: 100
Related to: 10